Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor α-chain are excluded from the analysis
Laure Michel, … , Jean-Paul Soulillou, David-Axel Laplaud
Laure Michel, … , Jean-Paul Soulillou, David-Axel Laplaud
Published September 2, 2008
Citation Information: J Clin Invest. 2008;118(10):3411-3419. https://doi.org/10.1172/JCI35365.
View: Text | PDF
Research Article Autoimmunity

Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor α-chain are excluded from the analysis

  • Text
  • PDF
Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease that results in demyelination in the central nervous system, and a defect in the regulatory function of CD4+CD25high T cells has been implicated in the pathogenesis of the disease. Here, we reanalyzed the function of this T cell subset in patients with MS, but we depleted cells expressing IL-7 receptor α-chain (CD127), a marker recently described as present on activated T cells but not Tregs. Similar to other studies, we observed a marked defect in the suppressive function of unseparated CD4+CD25high T cells isolated from MS patients. However, when CD127high cells were removed from the CD4+CD25high population, patient and control cells inhibited T cell proliferation and cytokine production equally. Likewise, when the CD25 gate used to sort the cells was stringent enough to eliminate CD127high cells, CD4+CD25high T cells from patients with MS and healthy individuals had similar regulatory function. Additional analysis indicated that the CD127high cells within the CD4+CD25high T cell population from patients with MS appeared more proliferative and secreted more IFN-γ and IL-2 than the same cells from healthy individuals. Taken together, we conclude that CD4+CD25highCD127low Tregs from MS patients and healthy individuals exhibit similar suppressive functions. The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS.

Authors

Laure Michel, Laureline Berthelot, Ségolène Pettré, Sandrine Wiertlewski, Fabienne Lefrère, Cécile Braudeau, Sophie Brouard, Jean-Paul Soulillou, David-Axel Laplaud

×

Figure 1

Frequency, proliferation, and suppressive activity of the top 4% of sorted CD4+CD25high T cells from MS patients and HIs.

Options: View larger image (or click on image) Download as PowerPoint
Frequency, proliferation, and suppressive activity of the top 4% of sort...
(A) Comparison of the percentage of CD4+CD25high T cells from MS patients and controls. The cut-off for high-staining CD25 was placed at 6 × 103 of mean fluorescence intensity. No statistical difference can be shown between the groups (patients, n = 21; HI, n = 17). (B) Regulatory properties of CD4+CD25high cells were examined in 11 untreated patients with RR-MS and 11 healthy controls. Cocultures of CD4+CD25– and CD4+CD25high cells were performed at a 1:1 ratio and under anti-CD3 stimulation. Proliferation was measured by incorporation of 3H-thymidine after 5 days of incubation. The percentage of suppression of responding cell proliferation (CD4+CD25–) by CD4+CD25high cells was determined as 1 – (proliferation of coculture / proliferation of responder population alone) × 100, where proliferation is expressed as cpm. CD4+CD25high T cells from MS patients exhibited less suppressive activity when the gate for sorting was positioned as shown in Supplemental Figure 1 (P < 0.05, Mann-Whitney U test). Mean values in A and B are indicated by horizontal lines. (C) Comparison of the proliferation of CD4+CD25high T cells in MS patients and HIs relative to the proliferation of the CD4+CD25– T cell subset. Proliferation of CD4+CD25high cells was not significantly different between patients (n = 11) and HIs (n = 11). When the top 4% of CD4+CD25high T cells were sorted, the cells were not fully anergic, suggesting the presence of activated T cells. Data represent mean ± SD.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts